Phenotypic analysis of PBMCs from uterine cervix cancer patients with high natural killer activity.
Phenotypic analysis of peripheral blood mononuclear cells from uterine cervix cancer patients, with increased natural killer cell activity, treated with radiation therapy was carried out. An increase in the percentage of CD56+ cells was observed in 5 out of 7 patients. When the expression of CD69, a phenotypic marker of cellular activation, was analyzed in 6 patients, an increase was observed in 4 of them. No direct correlation between cytolytic activity and the levels of CD56+ or CD69+ cells were observed. After 72 hr, an increased expression of CD56 was observed in 3 patients and a similar picture was seen at the same time following activation with IL-2 or IFN.
Pinel
M I
MI
Department of Radiation Therapy, National Cancer Institute, Rio de Janeiro, Brazil. atalecio@iis.com.br
Pires
V
V
Harab
R C
RC
Rumjanek
V M
VM
D000328:Adult; D015703:Antigens, CD / Q000032:analysis*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis*; D001918:Brachytherapy; D019002:CD56 Antigen / Q000032:analysis*; D002277:Carcinoma / Q000097:blood / Q000276:immunology* / Q000532:radiotherapy; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D037181:Lectins, C-Type; D008213:Lymphocyte Activation; D008875:Middle Aged; D011882:Radiotherapy, High-Energy; D011994:Recombinant Proteins; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000276:immunology* / Q000532:radiotherapy; D000099192:CD69 Antigens
D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D019002:CD56 Antigen; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D037181:Lectins, C-Type; D011994:Recombinant Proteins; D000099192:CD69 Antigens